Compound Pharmacy Beyond-Use Dating: USP 795/797 Guide

The beyond-use date is not a suggestion and it is not a guess

There is a specific moment in every compounding pharmacy inspection that separates the pharmacies that have their act together from the pharmacies that are about to have a very bad afternoon. The inspector picks up a compounded preparation from the shelf, reads the label, sees a beyond-use date, and asks a single question: "Show me the documentation that supports this date."

That question has exactly two possible outcomes. Either you produce a master formulation record with a BUD assignment supported by stability data, literature references, or the default USP guidelines, complete with a reasoning chain that connects the specific preparation characteristics to the specific date on the label -- or you produce something that amounts to "we've always done 30 days" and the inspector starts writing.

Beyond-use dating is where compounding pharmacy compliance lives or dies. Not because it is the most complex regulatory requirement you face (it is not), but because it sits at the intersection of scientific judgment, documentation discipline, and patient safety in a way that makes it the perfect proxy for overall operational quality. An inspector who finds sloppy BUD assignments has strong reason to believe the rest of your compounding operation is equally sloppy, and they will dig accordingly. An inspector who finds rigorous, well-documented BUD practices generally extends a degree of professional trust to the rest of the operation. The BUD is, in practice, the first impression your pharmacy makes during a compounding inspection.

USP 795 governs non-sterile compounding. USP 797 governs sterile compounding. Both were substantially revised in 2023, with the revised chapters becoming official on November 1, 2023 after years of delays, public comment periods, and legal challenges. The BUD frameworks in both chapters changed meaningfully from their prior versions, and if you are still operating under the pre-revision BUD defaults, you are non-compliant today. Not "at risk of non-compliance." Non-compliant.

USP 795: non-sterile compounding BUD rules that actually apply

The revised USP 795 established a tiered BUD framework for non-sterile preparations that replaced the old, relatively generous defaults with a more conservative structure. Understanding the tiers is not optional -- it is the foundation of every BUD assignment you make.

For non-aqueous formulations and solid dosage forms (capsules, tablets, powders, ointments with no water content), the default BUD when prepared from USP-grade ingredients and stored under appropriate conditions is 180 days. This is the most generous default, and it applies because water is the primary driver of microbial growth and chemical instability in most compounded preparations. No water, longer shelf life. But this default assumes you are using ingredients that are themselves within their manufacturer expiration dates and that your storage conditions are controlled and documented. If any ingredient in the formulation has a manufacturer expiration date that falls within your 180-day window, the BUD cannot extend beyond that ingredient's expiration. This is a detail that trips up pharmacies constantly: you compound a capsule formulation on January 1 with a 180-day default BUD of June 30, but one of the active ingredients expires on April 15. Your BUD is April 15, not June 30. The chain is only as strong as the weakest ingredient.

For aqueous formulations and preparations containing water (solutions, suspensions, creams, gels, any formulation where water is a component), the default BUD drops dramatically to 35 days when stored in a refrigerator (2-8 degrees Celsius), or 14 days at controlled room temperature. This is a significant tightening from prior practice, and it reflects the reality that water-containing preparations support microbial growth even in the presence of preservatives, particularly when compounded in environments that, however clean, are not pharmaceutical-grade manufacturing facilities. If your pharmacy has been assigning 90-day BUDs to aqueous suspensions based on older guidance or "we've always done it this way," you now need either stability data to support the longer date or you need to shorten your BUDs. There is no third option.

The critical exception: stability testing. USP 795 explicitly allows extended BUDs beyond the defaults if you have supporting stability data. This can come from published literature (peer-reviewed studies demonstrating stability for the specific formulation at the specific concentration under the specific storage conditions), from the preparation being an essentially copy of an FDA-approved product (in which case you can reference the approved product's expiration data, though the USP is clear that the BUD still cannot exceed the commercial product's labeled expiration period), or from pharmacy-specific stability testing conducted according to appropriate methodology. We will come back to the stability testing piece, because it is where some of the most common compliance failures originate.

What has to be on the label. Every non-sterile compounded preparation must be labeled with the BUD as a calendar date (not "30 days" or "6 months" -- an actual date), the storage conditions required to support that BUD, and the preparation identification that links back to the compounding record. This sounds elementary, and it is, which is why finding labels without calendar dates or without storage conditions during an inspection is such a damaging finding -- it suggests the pharmacy does not take the basics seriously.

USP 797: sterile compounding BUD rules and why they are more complex than you remember

Sterile compounding BUD rules under the revised USP 797 underwent some of the most significant changes in the chapter's history, and the complexity increase is not trivial. The revision reorganized BUD categories around two key variables: whether the preparation is compounded under Category 1 conditions or Category 2 conditions, and whether the preparation undergoes a sterility test.

Category 1 conditions apply to compounding done in a segregated compounding area (SCA) or a facility that meets a defined but less stringent set of engineering and environmental controls. Under Category 1, BUDs are short by design: 12 hours at controlled room temperature, or 24 hours under refrigeration. These are not generous timelines, and they are intentionally restrictive because the environmental controls in a Category 1 setting provide less assurance of sterility than a full cleanroom suite. If you are compounding CSPs (compounded sterile preparations) in a segregated area and assigning BUDs longer than these windows, you are out of compliance unless you can demonstrate that your facility actually meets Category 2 requirements.

Category 2 conditions require a classified cleanroom suite with ISO Class 5 primary engineering controls (your laminar airflow workbench or compounding aseptic isolator), ISO Class 7 buffer rooms, and ISO Class 8 ante-rooms, all with appropriate pressure differentials, HEPA filtration, and environmental monitoring programs. Under Category 2, the BUD framework is more generous but still tiered:

Without sterility testing, the default BUDs are: 4 days at controlled room temperature (20-25 degrees Celsius), 10 days refrigerated (2-8 degrees Celsius), and 45 days frozen (minus 25 to minus 10 degrees Celsius). These apply when you are using sterile ingredients and components, compounding in a properly classified environment, and following all applicable procedures. Note that 4 days at room temperature is still quite restrictive for many pharmacy operations, particularly those compounding batches for anticipated demand rather than patient-specific prescriptions.

With sterility testing conducted according to USP 71 methodology, Category 2 BUDs extend significantly: 30 days at controlled room temperature, 45 days refrigerated, and 60 days frozen. The jump from 4 days to 30 days at room temperature is enormous and represents a fundamental operational advantage for pharmacies willing to invest in sterility testing capability. But the testing must be done correctly, and this is where a significant percentage of compounding pharmacies stumble.

The in-use time limitation. This is the provision that catches pharmacies who focus on the BUD but forget about what happens after the preparation leaves the shelf. Once a CSP is punctured, entered, or otherwise compromised from its original sealed state (for example, a multi-dose vial that gets its first needle stick), the in-use time begins. The in-use time is separate from and shorter than the BUD and reflects the increased contamination risk from repeated entries. Your documentation must track both the BUD (from compounding) and the in-use time (from first access), and the preparation expires at whichever comes first.

The five BUD mistakes that generate the most inspection findings

I have seen enough compounding pharmacy inspection reports to identify the patterns. These five mistakes account for the vast majority of BUD-related findings, and all of them are preventable.

Mistake 1: Using the wrong default tier. A pharmacy compounds an oral suspension containing purified water and assigns it a 180-day BUD because "it's a capsule ingredient in liquid form." No. It contains water. It is an aqueous preparation. The 35-day refrigerated or 14-day room temperature default applies. The pharmacist's mental model of the preparation does not override the physical reality that it contains water and will support microbial growth. Inspectors catch this by reading the formulation record, noting the presence of water, and comparing the assigned BUD to the applicable USP default. It is not a subtle finding.

Mistake 2: Ignoring ingredient expiration dates. The BUD of a compounded preparation cannot extend beyond the earliest expiration date of any ingredient used in the preparation. This is explicitly stated in both USP 795 and 797, and it is violated with astonishing frequency. The root cause is usually operational: the pharmacist calculates the BUD based on the formulation type and storage conditions, but does not cross-reference against the ingredient expiration dates because that would require checking each ingredient container at the time of compounding and documenting the expiration dates in the compounding record. The fix is procedural -- make ingredient expiration date verification a required step in the compounding workflow, documented in the compounding record, checked during verification.

Mistake 3: Claiming stability data that does not actually support the assigned BUD. This is the most consequential mistake because it creates a false sense of compliance. A pharmacy assigns a 90-day BUD to an aqueous preparation and cites a published stability study. The inspector asks to see the study. One of three things happens: the study tested a different concentration than what the pharmacy compounds, the study tested under different storage conditions, or the study does not actually exist and the pharmacist was relying on secondhand information from a compounding forum or a supplier's technical bulletin that referenced stability without providing the underlying data. In any of these cases, the BUD is unsupported, and every preparation dispensed with that BUD is a compliance failure.

Mistake 4: Failing to document the BUD rationale. Even when the assigned BUD is correct, the failure to document why it is correct creates an inspection finding. The master formulation record must include the BUD assignment and its basis -- either the applicable USP default category (with enough detail to show you applied the right category) or the specific literature reference or stability data that supports an extended BUD. "90 days per stability data" is not sufficient documentation. "90 days based on [Author, Journal, Year] demonstrating chemical and physical stability of [drug] at [concentration] in [vehicle] stored at [conditions] for [duration]" is sufficient documentation. The difference is specificity and traceability.

Mistake 5: Not adjusting BUDs when you change formulations. You have been compounding a particular cream at 2% concentration with a well-documented 90-day BUD based on published stability data. A prescriber requests the same drug at 5% concentration. The pharmacist uses the same BUD. But the stability study was conducted at 2%, and drug stability is concentration-dependent. At 5%, the drug may degrade faster, the vehicle may behave differently, the preservative efficacy may be altered. The BUD from the 2% study does not transfer to the 5% formulation. You either need stability data for the 5% preparation specifically, or you default to the applicable USP category BUD. This mistake is common because it feels like a small change, but from a stability science perspective, concentration changes are not small changes.

Stability testing: what counts and what does not

Stability testing is the mechanism by which compounding pharmacies can extend BUDs beyond USP defaults, and it is also the area where the gap between what pharmacies think they are doing and what they are actually doing is widest.

What constitutes acceptable stability data. Published, peer-reviewed studies testing the specific formulation (drug, concentration, vehicle, preservative system) under the specific storage conditions you intend to use, with stability-indicating assay methods that can distinguish the intact drug from degradation products. The key phrase is "stability-indicating" -- a simple potency assay that measures total UV absorption at a given wavelength cannot distinguish between the active drug and a degradation product that absorbs at the same wavelength. If the assay is not stability-indicating, the data is unreliable, and inspectors with scientific training (which an increasing number of state board inspectors have) will identify this gap.

Third-party stability testing. Several laboratories offer stability testing services for compounding pharmacies, and using them is entirely legitimate. The critical requirement is that the testing must be performed on preparations that are representative of what your pharmacy actually compounds -- same ingredients, same equipment, same process, same personnel, same environment. Sending a carefully prepared sample to a testing lab when your daily operations involve less careful preparation under different conditions does not produce stability data that is applicable to your actual preparations. Inspectors have started asking not just for the stability report but for documentation showing that the test samples were prepared using the pharmacy's standard compounding procedures.

The "essentially a copy" pathway. If your compounded preparation is essentially a copy of a commercially available FDA-approved product (same active ingredient, same route of administration, same dosage form, same strength), you can reference the commercial product's approved expiration data. But USP 795 imposes conditions: the compounded product's BUD still cannot exceed the commercial product's labeled expiration, the preparation must be compounded from the same or equivalent ingredients, and your basis for claiming "essentially a copy" must be documented. This pathway is frequently misapplied -- pharmacies compound a preparation that is vaguely similar to a commercial product and claim the commercial BUD without documenting the actual comparison.

What does not constitute acceptable stability data. Supplier technical bulletins that state "stable for X months" without providing the underlying methodology and data. Forum posts from other compounding pharmacists describing their experience. Your own observation that "it still looks and smells fine after 90 days." Anecdotal experience is not stability data, and the fact that you have been assigning a particular BUD for years without apparent problems does not validate it. The preparation may have been degrading below potency specifications without visible signs, and your patients may have been receiving sub-therapeutic doses the entire time. That is not a compliance problem -- it is a patient safety problem, which is worse.

Documentation requirements that survive the inspection binder test

The "inspection binder test" is my term for a simple thought experiment: if an inspector picked up any compounded preparation in your pharmacy and asked you to produce every document connected to it, could you do it within five minutes? The documents in question form a chain, and every link must be present.

The master formulation record (MFR). One per formulation, not one per batch. The MFR contains the formulation name, dosage form, route of administration, all ingredients with quantities and quality specifications, compounding procedure with step-by-step instructions detailed enough that a qualified pharmacist who has never seen this formulation before could reproduce it, equipment required, BUD assignment with documented rationale, storage conditions, quality control procedures (including any testing performed on the final preparation), packaging requirements, and labeling requirements. The MFR is the recipe. It gets created once and revised when anything changes. Every batch compounded references the current MFR version.

The compounding record (CR). One per batch. The CR documents what actually happened during the compounding of a specific batch: date and time of compounding, MFR version referenced, each ingredient with manufacturer, lot number, expiration date, and quantity actually used (not just the quantity specified in the MFR -- the quantity measured and added), equipment used (identified by serial number or other unique identifier), environmental conditions if relevant (temperature, humidity), name and initials of the person who compounded, name and initials of the pharmacist who verified, yield (actual versus expected, with investigation documentation if the variance exceeds acceptable limits), quality control results, assigned BUD with basis documented (either referencing the MFR if unchanged or documenting any batch-specific adjustment), and sample retention information if applicable.

The ingredient verification trail. For each ingredient used in a batch, you must be able to demonstrate that the ingredient was of appropriate quality (USP, NF, or another compendial grade for pharmaceutical ingredients; analytical grade for non-compendial ingredients), that it was within its manufacturer expiration date at the time of use, and that it was stored under conditions appropriate for its stability. This means your ingredient inventory system must track lot numbers, expiration dates, and receipt dates, and your compounding records must reference these lot numbers so that any batch can be traced back to its specific ingredient lots.

Equipment calibration and maintenance records. Balances must be calibrated and the calibration documented. Laminar airflow workbenches (for sterile compounding) must have certification records showing ISO Class 5 performance. Refrigerators and freezers must have temperature monitoring records. If any of this documentation is missing, the inspector cannot verify that the equipment used in compounding was functioning within specifications, which means the BUD assigned to preparations compounded with that equipment is unsupported.

How batch-level tracking changes everything about BUD compliance

Here is the operational reality that most compounding pharmacies eventually discover: documentation-based BUD compliance is only as good as your ability to connect a specific preparation on the shelf to a specific compounding record, which connects to a specific set of ingredient lots, which connect to specific supplier certificates of analysis, which demonstrate that the ingredients were of appropriate quality. This chain of traceability is not optional -- it is what inspectors test when they pick up a preparation and start asking questions.

Without batch-level tracking, this chain breaks almost immediately. The preparation on the shelf has a BUD on the label, but which compounding record does it correspond to? If you compounded three batches of the same formulation in the last month, which batch is this specific container from? Which ingredient lots went into it? Were those ingredients within their expiration dates at the time of compounding? The pharmacist might remember, or might be able to figure it out by cross-referencing dates and quantities, but "figure it out" is not the same as "demonstrate it," and inspectors require the latter.

Batch-level tracking assigns a unique identifier to each compounding batch and carries that identifier through the entire lifecycle of the preparation: from the compounding record through labeling, storage, dispensing, and (if applicable) disposal. When an inspector picks up a container, the batch number on the label connects to the compounding record, which lists the specific ingredient lots, which connect to receiving records and certificates of analysis. The chain is complete, documented, and verifiable in minutes rather than hours.

This matters operationally in three specific ways. First, it makes recalls and quality investigations tractable. If you discover that an ingredient lot was defective or that an environmental monitoring result suggests contamination during a specific time period, batch-level tracking lets you identify exactly which preparations are affected and which patients received them. Without it, you are either recalling everything compounded during the time period (overreaction that destroys patient confidence and wastes inventory) or recalling nothing and hoping (underreaction that puts patients at risk).

Second, it makes BUD adjustments auditable. If you need to shorten the BUD on a preparation because of a stability concern or ingredient issue, batch-level tracking lets you identify every container affected and pull them from inventory or relabel them. Without it, you are searching through shelves trying to identify which containers might be from the affected batch, and you will miss some.

Third, it makes inspections faster and less stressful. The inspector asks for documentation. You look up the batch number. You produce the compounding record, the ingredient lot details, the quality control results, the BUD rationale, and the dispensing history. The inspector checks a few data points, finds them consistent, and moves on to the next preparation. The alternative -- the inspector asks for documentation, you start searching through binders and spreadsheets, the inspector waits, you find some documents but not others, the inspector asks follow-up questions that require more searching -- is how findings accumulate and how inspections go from routine to adversarial.

The state board enforcement landscape for BUD violations

State boards of pharmacy have become measurably more sophisticated in their approach to compounding oversight since the NECC disaster in 2012, which killed 76 people and sickened more than 750 from contaminated methylprednisolone acetate injections. BUD compliance is a primary focus area in post-NECC enforcement. The enforcement pattern is consistent across states: BUD violations are treated as serious findings because they directly implicate patient safety.

A preparation dispensed with an unsupported BUD may have degraded below therapeutic potency, meaning the patient is receiving an ineffective treatment. For sterile preparations, an inappropriately long BUD increases the window for microbial contamination and endotoxin development. For preparations containing drugs with narrow therapeutic indices, sub-potency due to degradation can have immediate clinical consequences. Inspectors understand these connections, and they communicate them in their findings.

The penalty framework for BUD violations typically starts at $1,000 to $5,000 per finding for documentation deficiencies (missing BUD rationale, incomplete compounding records), escalates to $5,000 to $15,000 per finding for unsupported BUD assignments (claiming extended BUDs without adequate stability data), and can reach $10,000 to $25,000 or more for findings involving patient harm or systematic non-compliance. These are per-finding figures, and an inspection that identifies BUD issues across multiple preparations can produce cumulative penalties that are financially significant. License restrictions that limit or suspend compounding activities until corrective actions are verified are increasingly common, and for pharmacies where compounding represents a substantial portion of revenue, a compounding suspension is an existential financial event.

The FDA also has jurisdiction over compounding pharmacies under the Drug Quality and Security Act (Section 503A for traditional compounding pharmacies and Section 503B for outsourcing facilities). FDA inspections tend to be more technically rigorous than state board inspections, and BUD-related findings from FDA inspections have resulted in warning letters, import alerts (for pharmacies shipping across state lines), and in extreme cases, injunctions and consent decrees. The FDA's expectations around stability data supporting extended BUDs are particularly stringent -- they evaluate the scientific adequacy of the stability studies themselves, not just their existence.

Building a BUD compliance system that works on an ordinary Tuesday

The compounding pharmacies that consistently pass inspections without significant BUD findings share a set of operational characteristics that are more about discipline than sophistication. They have invested in clear procedures, consistent execution, and documentation systems that make the right thing the easy thing.

Their master formulation records are current, version-controlled, and reviewed at defined intervals. Their compounding records are completed in real time during compounding, not reconstructed afterward from memory. Their ingredient management systems track lot numbers and expiration dates and flag ingredients that are approaching expiration before they get used in a batch. Their BUD assignments are documented with specific references to the data or guideline that supports them, and those references are checked when formulations are reviewed. Their quality control procedures include periodic review of assigned BUDs against current literature and USP requirements.

None of this requires exotic technology. It requires a system -- whether that is software, paper-based procedures, or a combination -- that makes documentation the path of least resistance rather than an afterthought. The pharmacies that struggle are not staffed by incompetent people. They are staffed by competent people working in systems that make compliance harder than it needs to be, where the compounding record is a form that takes 15 minutes to fill out properly, where the BUD rationale documentation is a separate binder in a different room, where the ingredient lot numbers are on the containers that have already been put away.

The goal is not zero findings. The goal is a system where every preparation on your shelf can be traced to a complete compounding record within minutes, where every BUD is supported by documented rationale that you can explain to an inspector, where every ingredient is verified and documented, and where deviations are caught by the system rather than by the inspector. That is what BUD compliance looks like when it actually works, and it is the difference between a pharmacy that dreads inspections and a pharmacy that treats them as a routine verification of what it already knows to be true.

ShelfLifePro tracks every compounded batch from ingredient receipt through dispensing -- with lot-level traceability, BUD verification, and inspection-ready documentation that you can pull up in seconds, not hours. Built for compounding pharmacies that want to pass inspections without the panic.